Shraddha Thakkar, Ting Li, Zhichao Liu, Leihong Wu, Ruth Roberts, Weida Tong
Drug discovery today 2020 JanDrug-induced liver injury (DILI) is of significant concern to drug development and regulatory review because of the limited success with existing preclinical models. For developing alternative methods, a large drug list is needed with known DILI severity and toxicity. We augmented the DILIrank data set [annotated using US Food and Drug Administration (FDA) drug labeling)] with four literature datasets (N >350 drugs) to generate the largest drug list with DILI classification, called DILIst (DILI severity and toxicity). DILIst comprises 1279 drugs, of which 768 were DILI positives (increase of 65% from DILIrank), whereas 511 were DILI negatives (increase of 65%). The investigation of DILI positive-negative distribution across various therapeutic categories revealed the most and least frequent DILI categories. Thus, we consider DILIst to be an invaluable resource for the community to improve DILI research. Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.
Shraddha Thakkar, Ting Li, Zhichao Liu, Leihong Wu, Ruth Roberts, Weida Tong. Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity. Drug discovery today. 2020 Jan;25(1):201-208
PMID: 31669330
View Full Text